Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Rohto Pharmaceutical Co ( (JP:4527) ) has shared an announcement.
Rohto Pharmaceutical reported robust results for the nine months to December 31, 2025, with net sales up 12.0% to ¥253.1 billion and profit attributable to owners of parent rising 14.3% to ¥28.3 billion, while earnings per share improved to ¥125.15. The balance sheet also strengthened as total assets reached ¥460.7 billion and the equity ratio climbed to 62.3%, reflecting solid financial health.
The company raised its full-year forecast, now projecting a 10.3% increase in net sales to ¥340.5 billion and a 7.0% rise in profit attributable to owners of parent to ¥33.0 billion, alongside higher ordinary income expectations. Rohto also revised its dividend outlook upward, targeting a full-year payout of ¥44 per share, signaling confidence in cash generation and offering a more attractive return to shareholders.
The most recent analyst rating on (JP:4527) stock is a Buy with a Yen2876.00 price target. To see the full list of analyst forecasts on Rohto Pharmaceutical Co stock, see the JP:4527 Stock Forecast page.
More about Rohto Pharmaceutical Co
Rohto Pharmaceutical Co., listed on the Tokyo Stock Exchange, operates in the pharmaceuticals and healthcare sector, offering over-the-counter drugs, eye care, skincare and related consumer health products. The company continues to expand its global footprint, recently adding Rohto MediLuxe Europe S.A.S.U. to its consolidated group, underscoring its focus on overseas markets and cosmetic-related businesses.
Average Trading Volume: 618,885
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen604.2B
See more insights into 4527 stock on TipRanks’ Stock Analysis page.